Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

[EX Q]: "Crediting conservation in Austin, the Save Our Springs Alliance said in an Aug. 16, 2011, entry in its online newsletter: ""Ten years ago the Austin Water Utility used a total of 240.3 million gallons. Every summer since then our peak day of water use has been lower."" After noting that this year’s peak water use in a day was 217 million gallons, the entry continues: ""So raise a tall glass of ice water in honor of our success: water conservation gains have outpaced population growth for a decade. Add a ‘Salud!’ to another 10 years of flat or declining water use — easily achieved with cost-effective conservation measures and an emerging ‘culture of conservation,’ one that recognizes that we can thrive and be happy without oversized, overwatered New England-style turf grass lawns."" We can’t check on the next decade, but we can check if peak water usage has been less every year than what it was in 2001. Indeed, the Austin Water Utility sent us figures indicating that on the peak days of water consumption from 2002 through August 2011, customers used less water than the 240.3 million gallons used on Aug. 13, 2001, though that was barely so in one year. The greatest peak use day since 2001 was Aug. 26, 2006, when usage was 240.17 million gallons — about 5/100ths of a percent shy of the amount gulped, flushed and otherwise used in 2001. The lowest peak-use amount in the 10 years after 2001 was 176.98 million gallons on Aug. 13, 2007. Put another way, the average peak water use in a day in the period was about 214 million gallons, 11 percent off the 2001 peak. The utility’s director, Greg Meszaros, told us in an interview that conservation helps explain the lower peak-use amounts, though he said consumption generally bounces around year to year partly due to variations in the weather — rainy summers reduce demand — and the economy. Per-capita water consumption has been relatively flat, Meszaros said, since the utility instituted a conservation program in 2007 that, among features, encourages customers to use low-water appliances and limit lawn watering. According to the utility, customers have used less water per person lately than individuals did in past years. Per-capita daily use has averaged 190 gallons or more four times since 1990, the last time being 2006. Average per-person consumption slid to 151 gallons in 2007, reached 170 gallons in 2008 and then dipped two straight years, reaching less than 140 gallons in 2010. Daryl Slusher, an assistant director for the utility, said the average will approach 160 gallons for the year that ends Sept. 30. Save Our Springs maintains the area’s conservation successes demonstrate that a water treatment plant slated for Northwest Austin won’t be needed for many years. Meszaros told us Austin needs the new plant because two current plants can’t be relied on indefinitely. Also, he said, the new project will include a vital water transmission main easing the delivery of water to the fast-growing northern third of the utility’s service area. ""We’re not doing (the new plant) just to meet a peak water demand,"" Meszaros said. In an interview, Bill Bunch, SOS’s executive director, expressed skepticism about strains in the existing water delivery system. He also said there’s not sufficient water demand to justify the new one and forwarded an April 2002 recommendation from city staff about preliminary engineering for the new plant. The document states the plant would be needed by 2009 to meet increasing water demands, predicting too that the utility’s peak one-day demand in summer 2009 would be 281 million gallons; the peak amount that year turned out to be 228 million gallons. Utility spokesman Kevin Buchman later told us by email that in 2002, the ""main reason for moving forward with the construction of a new plant was to meet the projected demands."" He said, though, the utility’s mid-decade focus on conservation allowed the city to postpone the plant’s completion by more than five years. ""Also,"" Buchman said, ""since 2002 we have had one of our (originally three) plants decommissioned and our other two water plants have been expanded as much as possible."" We won’t try to settle the water plant debate here. But the alliance’s statement about peak water use rates ."
[EX A]: Ten years ago the Austin Water Utility used a total of 240.3 million gallons. Every summer since then our peak day of water use has been lower.

[EX Q]: The story makes clear the “big unknown” remains the price and “how much people are willing to spend to cut a day or so off of a bout of flu.” The story reports that Genentech, the drug’s manufacturer, said it’s too early to comment on the drug’s U.S. price. The story also notes that in Japan, where the drug was invented, it “sells for the equivalent of about $43.50.” The story uses terms like “a little more than a day” and “nearly a day” and “substantially” to describe the drug’s reduction in flu symptoms, fever, and coughing and sneezing, respectively. It does not explain, as the news release does, that: “Similar efficacy results were seen between baloxavir marboxil and [Tamiflu] in relation to duration of symptoms and fever reduction.” In other words, on the symptom front, both drugs were the same. According to the news release, a difference was seen in the length of time the virus was shed from the body (presumably through coughing and sneezing): 24 hours for baloxavir marboxil verses 72 hours for Tamiflu. The news release also states that there was also a difference seen in the level of virus in the nose and throat, but it provides no precise numbers. It is not known whether this benefit translates into less infection transmission, and the story should have made that clear. The news release issued by Genentech about the FDA’s decision to grant priority review describes baloxavir marboxil’s most common side effects: diarrhea, bronchitis, nausea and sinusitis. The news release also states that overall incidence of adverse events seen in patients taking baloxavir marboxil were lower than those seen in both the placebo group and the group taking Tamiflu. The STAT News story does not mention any potential harms. This evidence comes from the randomized phase III Capstone-1 study the FDA will review, which included 1,436 people in the US and Japan. It excluded people older than 64. The news story does not note this exclusion, nor does it state a key problem with this study: It has never been published in a peer-reviewed journal (instead, a study abstract was released as part of ID Week 2017). This means the full data analysis has never been seen by anyone other than the researchers. We explained why this is important in February 2018, when we discussed news coverage of the drug’s approval in Japan. The 2017-2018 flu season was the worst the US had experienced in nearly a decade. The flu impacted the entire country, and was responsible for 172 pediatric deaths. The news article did not use these or any other flu-related statistics to increase fear about the flu and, in turn, the need for this medication. The article includes two sources: Mark Eisner, Genentech’s VP of product development for immunology, infectious diseases and ophthalmology and Richard Webby, head of the World Health Organization’s influenza collaborating center at St. Jude Children’s Research Hospital in Memphis. Eisner’s affiliation with Genentech, the drug’s manufacturer, is clearly noted. Webby does not appear to have any conflicts of interest. The article would have been stronger if it had included a third source who commented on what–if anything–is known about whether reducing the duration of symptoms leads to reduced levels of transmission that result in fewer people contracting the flu and fewer deaths. The story explains that the only other drug approved to treat the flu is Tamiflu, which is not widely used. The writer explains that both drugs need to be taken within 48 hours of symptom onset and that baloxavir marboxil is a single one-time dose, while Tamiflu must be taken twice daily for five days. It is clear from the story that the FDA is expected to decide by the end of the year whether to approve this new flu medication. The story explains that it’s been more than 20 years since a new class of flu drug has been developed and marketed. (It is available in Japan.) The catalyst for the story was a news release issued by Genentech about the FDA granting priority review of baloxavir marboxil, but the story does not use direct quotes from the news release.
[EX A]: A flu drug — shown to reduce the duration of symptoms — could upend treatment in U.S.

[EX Q]: The green light for the combined use of Tafinlar, also known as dabrafenib, and Mekinist, or trametinib, from the Food and Drug Administration (FDA) is the first of its kind for a form of the disease with a specific genetic profile. Both drugs are already approved for separate use but GSK believes they will have a longer-lasting effect if given together. Industry analysts also see a combination offering the greatest commercial potential. Tafinlar, which is similar to Roche’s rival medicine Zelboraf, is designed to work in patients with a mutation of a gene known as BRAF. So-called BRAF inhibitors have been remarkably effective in shrinking melanoma tumors but most patients eventually develop resistance to the drugs. By combining Tafinlar with Mekinist, which works in a different way, the hope is that the cancer will be held at bay for longer. The FDA approval, which was announced late on Wednesday, covers the treatment of melanoma that cannot be removed by surgery or which has spread to other organs. Melanoma is diagnosed in nearly 160,000 people worldwide each year. It can spread quickly to internal organs and average survival is six to nine months.
[EX A]:
GSK melanoma drug combination wins accelerated U.S. approval.